Extensive studies have been performed and reports published during the last few years concerning the biochemical, physiological, and therapeutic actions of hyaluronidase, the most important of the "spreading factors." Very few of these studies have been concerned with the use of hyaluronidase as an aid to insulin shock therapy with regard to decreasing the amount of insulin necessary, accelerating the evolution of comas and thus increasing the period of actual treatment, and avoiding its untoward effects, particularly the so-called after-shocks. Although the value of insulin shock therapy is still controversial, this therapy continues to be widely used in mental hospitals throughout the world for the management of schizophrenia and other psychiatric disorders. Therefore, every method leading to possible technical improvements in the administration of this therapy is welcome and should be given attention.
Reports on the use of hyaluronidase in insulin shock therapy have been published by Straccia and Scheflein,
Tyndel M. HYALURONIDASE AS AN ADJUVANT IN INSULIN SHOCK THERAPY. JAMA. 1956;162(1):32–34. doi:10.1001/jama.1956.72970180002009a
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: